Drug intelligence / Profile preview

onfekafusp alfa + temozolomide

Development stage: Unknown
Lead developer: Philogen
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Intravenous, Oral

Overview

Onfekafusp alfa + temozolomide is a **combination therapy of an antibody-cytokine fusion protein (onfekafusp alfa, also known as L19TNF) and the alkylating chemotherapeutic agent temozolomide**, primarily investigated for use in aggressive cancers such as glioblastoma and soft tissue sarcoma[1][4][8]. - Onfekafusp alfa is a fusion protein consisting of the L19 antibody, which targets the ED-B domain of fibronectin expressed in tumor neovasculature, fused to the immune-activating cytokine tumor necrosis factor alpha (TNFα)[1][6][9]. - Temozolomide is a standard oral DNA-alkylating agent that is cytotoxic to cancer cells. This combination is being studied for potentially improving tumor-targeted immune response and direct tumor cytotoxicity beyond what is achieved with standard chemotherapy alone[1][4][8].

Brand names: Fibromun + temozolomide
Other names: onfekafusp alfa + temozolomideL19TNF + temozolomide

Targets

DNAED-B (Fibronectin extra domain B)TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)

Beyond the preview

Go deeper on onfekafusp alfa + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on onfekafusp alfa + temozolomide.

Explore the full profile